Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.47 |
| ▸ | RORC | P51449 | 3/20 | 0.46 |
| ▸ | HSD17B13 | Q7Z5P4 | 3/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13876799 | 0.92 | EPHX2 (0.57) | EPHX2NR1H4RORCHSD17B13DDR1 | |
| SCHEMBL13876801 | 0.89 | EPHX2 (0.57) | EPHX2NR1H4RORCDDR1SCN3A | |
| SCHEMBL13876802 | 0.88 | EPHX2 (0.54) | EPHX2NR1H4DDR1TP53 | |
| SCHEMBL13876530 | 0.88 | EPHX2 (0.70) | EPHX2NR1H4RORC | |
| SCHEMBL13876877 | 0.84 | HSD17B13 (0.44) | EPHX2NR1H4HSD17B13SCN3ATP53 | |
| SCHEMBL13876862 | 0.84 | EPHX2 (0.53) | EPHX2NR1H4RORCSCN3A | |
| SCHEMBL4197572 | 0.84 | EPHX2 (0.54) | EPHX2NR1H4RORCDDR1 | |
| SCHEMBL13876784 | 0.83 | EPHX2 (0.55) | EPHX2NR1H4HSD17B13SCN3ATP53 | |
| SCHEMBL4180231 | 0.80 | EPHX2 (0.52) | EPHX2NR1H4DDR1MAPK8 | |
| SCHEMBL13876226 | 0.80 | EPHX2 (0.61) | EPHX2NR1H4RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885NR1H4 142/4885RORC 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.